New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis [Yahoo! Finance]
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion [Yahoo! Finance]
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
The Business Case For Expanding Diversity In Clinical Trials [Forbes]
FDA approves Bristol Myers Squibb's Breyanzi for follicular lymphoma [Yahoo! Finance]